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Protocol: A cluster randomised trial of text messaging 
reminders for influenza vaccine in patients under 65 in 
clinical risk groups in English primary care 
 
1 Administrative information 
1.1 Title 
A cluster randomised trial of text messaging reminders for influenza vaccine in patients 
under 65 in clinical risk groups in English primary care. 
 
1.2 Trial registration 
Registered on clinicaltrials.gov. 
 
1.3 Protocol version 
Version 2.7, 11th February 2014 
 
1.4 Funding 
Wellcome Trust Senior Clinical Fellowship award. 
 
1.5 Roles and responsibilities 
Authors contributing to this protocol:  
 Emily Herrett, LSHTM 
 Liam Smeeth, LSHTM 
 Tjeerd van Staa, LSHTM 
 Diana Elbourne, LSHTM 
 Elizabeth Allen, LSHTM 
 Joanna Sturgess, LSHTM 
 Caroline Free, LSHTM 
 Hugo Harper, Cabinet Office 
 Michael Hallsworth, HMRC 
 Anna Sallis, Department of Health 
 Tim Collier, LSHTM 
 Tim Chadborn, Public Heath England 
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Trial sponsor: LSHTM 
1.6 Lay summary 
Influenza causes a substantial burden to the NHS and the UK as a whole.  Influenza vaccine 
is safe and effective but is required annually.  In 2012, the UK government recommended 
that at least 75% of elderly people (aged 65+) and 75% people under 65 with certain chronic 
conditions (e.g. chronic heart disease, diabetes, asthma, etc) should be vaccinated.  While 
primary care practices are achieving targets for the elderly, they are under-performing in 
patients with chronic conditions, missing a third of eligible patients in 2011/12.  Therefore 
strategies to increase flu vaccine uptake in these patients are required.   
Text messaging is already being used in some practices for flu vaccine reminders but there 
has been no trial assessing its effectiveness.  Therefore, we propose a trial of a text 
message flu vaccine reminder in patients aged under 65 who have a chronic condition.   
This study will randomise general practices to either standard care (seasonal flu campaign 
as planned), or to receive additional resources allowing them to send a targeted text 
messaging campaign to eligible patients aged under 65 and with a chronic condition.  
Vaccine uptake will be ascertained through the anonymised patient medical records. 
 
1.7 Review by ethics committees 
This protocol will be reviewed by: 
 the London School of Hygiene and Tropical Medicine Ethics Committee;  
 the Independent Scientific Advisory Committee at the Clinical Practice Research 
Datalink;  
 the Research Projects Committee at ResearchOne, and  
 the Surrey Borders National Research Ethics Committee.  
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2 Introduction 
2.1 Background and rationale 
2.1.1 Justification for a trial  
Influenza morbidity and mortality causes a substantial financial burden to the NHS and to the 
UK as a whole.  Influenza vaccine is safe and effective but is required annually because the 
circulating strain of virus changes each year.  In the UK in 2012, the Chief Medical Officer 
(CMO) has recommended that at least 75% of elderly people (aged 65+) and 75% people 
under 65 with certain chronic conditions (e.g. chronic heart disease, diabetes, asthma, etc) 
should be vaccinated. 
While primary care practices are achieving these targets for elderly patients, those set for 
patients with chronic conditions are not being met and have shown no substantial increases 
in the past decade1.  Therefore strategies to increase flu vaccine uptake in these patients 
are required.   
Several randomised trials have demonstrated the effectiveness of flu vaccine reminders 
delivered to patients by letter, postcard or telephone.2, 3  However, use of text messaging in 
the NHS for appointment reminders is increasing as it is cheap, quick and effective.  Text 
messaging is already used in roughly 30% of practices to remind patients about their flu 
vaccine4 but there has been no trial addressing its effectiveness.  Trials of text messaging in 
the US have shown some success as vaccine reminders, but whether there is an effect in 
UK primary care is unknown.  Therefore, we propose a cluster randomised trial of a text 
messaging flu vaccine reminder in patients aged under 65 who have a chronic condition. We 
will randomise whole primary care practices to either standard care or a text messaging 
campaign to eligible patients.  
 
2.2 Objectives 
Primary 
(i) To estimate the level of vaccine uptake in intervention and standard care groups 
(ii) To evaluate the feasibility of recruiting and randomising practices to a text 
messaging intervention trial; 
(iii) To evaluate the feasibility of practice delivery of a text message intervention to 
eligible patients within a primary care setting; 
(iv) To evaluate the feasibility of ascertaining practice data regarding text message 
delivery and flu vaccine uptake. 
Secondary 
(v) To explore the acceptability of text messaging in a sample of patients 
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2.3 Trial design 
A cluster randomised trial in three settings.   
3 Methods 
3.1 Participants, interventions and outcomes 
3.1.1 Study setting 
Three settings in UK primary care: 
1. Practices contributing data to the Clinical Practice Research Datalink (CPRD), a 
primary care database; 
2. Practices contributing data to ResearchOne, a primary care database; 
3. Practices in London using iPlato software: Initially practices in Islington and 
Barnet, widening to all London boroughs to meet recruitment targets. 
 
3.1.2 Eligibility criteria 
Eligible practices will be those in one of the three settings described above that already use 
a text messaging system to communicate with patients about issues other than influenza 
vaccination.   Within CPRD and practices in London, this system is iPlato5.  Islington and 
Barnet have high iPlato coverage and therefore are ideal study settings.  All practices within 
these boroughs will be targeted initially.  We will then widen our recruitment to all iPlato 
practices to increase recruitment.  Within CPRD, practices which have sent >100 text 
messages to patients for non-flu vaccine related issues will be identified and contacted 
(assuming other eligibility criteria are met).  Within ResearchOne practices use TPP 
software, which has text messaging capability.  Therefore all practices are automatically 
eligible.  Practices using any other text messaging software will be excluded.   
We will also exclude:  
(i) Practices that used text messages for influenza vaccination reminders in the 
2012/13 influenza season because their planned seasonal flu campaign is likely 
to include a text message to the target group.  In CPRD and ResearchOne, this 
will be established by interrogating the practice medical records.  In London 
practices using iPlato, the software company will provide this information. 
(ii) Practices whose Clinical Commissioning Group (primary care trust) aims to send 
out a targeted text message campaign in all practices.  The text messaging 
software company work with the seasonal influenza leads in each Clinical 
Commissioning Group and will be able to provide this information. 
 
3.1.3 Interventions 
This is a cluster trial6, 7 in which whole general practices will be randomised to the 
intervention or control group. 
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Practices in the intervention arm will be asked to deliver a text message intervention to 
patients.  Practices will receive additional support for this, comprising guidance notes 
regarding delivery of the message (content, timing, eligible patients) and payment for the 
time of a practice administrator to deliver the intervention.   
The text message intervention will be an influenza vaccination reminder to patients who are 
under 65 in a clinical risk group (with chronic heart disease, chronic neurological disease, 
diabetes, chronic kidney disease, chronic liver disease, chronic respiratory disease, 
immunosuppression), as set out by the Chief Medical Officer.  The Chief Medical Officer also 
recommends that pregnant women are vaccinated but due to difficulties in identifying 
pregnant women, and ethical issues regarding contacting them, we will not ask intervention 
practices to send a text message to them.   
Practices will identify eligible patients based on their electronic medical records.  Practices 
will have established systems for this using their practice software and we will not ask them 
to change this process.   
The message content that practices will be asked to send is: 
“Hello PATIENT NAME, to reduce your risk of serious health problems from flu 
we recommend vaccination. Call PRACTICE PHONE NUMBER to 
book. PRACTICE NAME” 
Intervention practices may be contacted up to three times during their flu season to remind 
and offer assistance from the text messaging software company with sending the text 
message to eligible patients.   
Practices in ResearchOne: During the trial, ResearchOne collaborators will keep a record 
of intervention practices that have sent the text message, and will update the Chief 
Investigator fortnightly with this list.  A named contact at practices that have not sent the 
message will be contacted by email by a member of the Trial Management Team up to three 
times to remind them to send the message.  This will be done at weekly intervals from the 
start of the influenza campaign.  Practices will be reminded that they can use the F1 help 
service in the TPP software for assistance in sending the message. 
Practices in CPRD or in London using iPlato: During the trial, the iPlato software 
company will keep a record of intervention practices that have sent the text message, and 
will update the Chief Investigator weekly with this list.  A named contact in practices that 
have not sent the message will be contacted by email by a member of the Trial Management 
Team up to three times to remind them to send the message.  This will be done at weekly 
intervals from the start of the influenza campaign.  Practices will be reminded that they can 
contact iPlato for assistance with sending the message. 
An online or hard copy posted questionnaire will also be sent to practices in the intervention 
arm to ascertain feedback from practice staff about delivery of the intervention.  
The comparison group will be asked to continue with their seasonal flu campaign as planned 
(standard care). 
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3.1.4 Sub-study for patient feedback 
A small sub-study will also be conducted in 2 participating intervention practices.  Each of 
these practices will send a short anonymous questionnaire to patients that were targeted in 
the seasonal influenza campaign.  This questionnaire will be anonymised, with no personal 
identifiers and mailed back to the Chief Investigator in a stamped addressed envelope.   
  
Protocol version 2.7, 11/02/2014 
Page 7 of 16 
 
3.1.5 Outcomes 
Primary outcomes 
Objective (i): To estimate the level of vaccine uptake in intervention and standard care 
groups.  We will measure: 
 Influenza vaccine uptake, stratified by risk group; 
 
Secondary outcomes: 
Objective (ii): To evaluate the feasibility of recruiting and randomising practices to a text 
messaging intervention.  We will measure: 
 Practice recruitment rate; 
Objective (iii): To evaluate the feasibility of practice delivery of a text message intervention 
to eligible patients within a primary care setting.  We will measure: 
 Extent that text messages are sent by practice to eligible patients; 
 Practice acceptability of message, including aspects of delivery, content, results; 
 Cost to practice of delivering intervention; 
Objective (iv): To evaluate the feasibility of ascertaining practice data regarding text 
message delivery and flu vaccine uptake.  We will measure: 
 Availability of data to examine text message receipt in each risk group; 
 Availability of data to examine vaccine uptake in each risk group; 
 Time and cost required to gather data. 
 Level of vaccine uptake in intervention and standard care groups; 
Objective (v):  Acceptability of text messaging to patients. 
 
  
Protocol version 2.7, 11/02/2014 
Page 8 of 16 
 
3.1.6 Practice timeline 
The practice timeline is described in the table below.   
  Study period 
  Enrolment Allocation Post allocation Closeout 
Time point Aug 2013 Sept 2013 
Sep to 
Dec 2013 Dec 2013 Feb 2014 
Enrolment:      
    
Eligibility screen x    
    
Informed consent x    
    
Allocation   x  
    
Interventions:      
    
Intervention     x     
Control     x     
Assessments:      
    
Practices complete 
questionnaire 
    
 
x   
Researchers extract 
relevant data from 
practice (age, sex, 
clinical risk group, 
influenza vaccination 
reminder types, vaccine 
uptake) 
        x 
Questionnaire to patients 
in the substudy    
x 
 
 
 
3.1.7 Sample size 
At 90% power and 5% significance, we will require 180 practices to identify an increase in 
vaccine uptake from 54% to 57%. This 5.5% increase is a conservative estimate based on 
previous text messaging and vaccine reminder studies.2 We have therefore chosen to recruit 
and randomise 200 practices with approximately 750 eligible patients per practice.  This is 
based on a design effect of 0.02404; this was estimated based on clustering of influenza 
vaccine uptake in the 2011/12 influenza season for general practices in the CPRD.   
 
3.1.8 Recruitment 
3.1.8.1 CPRD 
The Chief Investigator will identify eligible practices in the CPRD.  The anonymised practice 
records of the CPRD will be interrogated to identify practice use of text messaging in the 
2012/13 influenza season.  Text messages to patients are recorded as Read codes.  Any 
practice with >100 text message Read codes to patients will be defined as a frequent user of 
text messaging software.  Practices that used text messaging for vaccination reminders in 
the 2012/13 influenza season will be excluded.   
Eligible practices will be contacted by mail to ascertain their interest in the trial, to identify 
which software system is used and to establish whether the practice meets eligibility criteria.  
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Any interested practice that meets the eligibility criteria will be sent a consent form and 
further information regarding the study.   
 
3.1.8.2 ResearchOne 
All practices using TPP SystmOne software are potentially eligible for the trial as all have the 
facility to use the in-built text messaging software.  Practices will be contacted by the Chief 
Investigator and asked for expressions of interest.  At the time of expressing interest, 
practices will give consent for their anonymised records to be interrogated.  Based on the 
practice records, the ResearchOne team will identify practices that sent a targeted text 
message campaign in the 2012/13 influenza season, and will also identify the CCG in which 
the practice sits.  These data will allow eligibility criteria to be applied.   
Any interested practice that meets the eligibility criteria will be sent a consent form and 
further information regarding the study.   
 
3.1.8.3 London practices using iPlato software 
Initially, practices in Islington and Barnet will be contacted via email for initial expressions of 
interest.  Practices will be contacted by a member of Noclor, the North and Central London 
Research Consortium.  Interested practices will be directed to the Chief Investigator or to a 
study website, where they will be able to access the practice information sheet and consent 
form.  A formal letter of invitation, practice information sheet and consent forms will be sent 
to interested practices.  To increase recruitment, we will also target practices using iPlato 
across other London boroughs. 
 
3.1.8.4 Recruitment to the sub-study 
After recruitment to the main study, practices in the intervention arm will be randomly 
selected for invitation to the sub-study.  We aim to recruit two practices. 
 
3.2 Assignment of interventions 
3.2.1 Randomisation procedure 
We will use block randomisation within each setting.  In the CPRD and ResearchOne, we 
will stratify by region.  In Islington and Barnet, we will stratify by borough. 
We will randomise using random permuted blocks of size 2, 4 and 6.  (Group 1 is the 
standard care, group 2 is intervention).  20% of blocks will be size 6, 50% of blocks size 4 
and 30% of size 2.  The randomisation will be blinded to practice name, and the study team 
will not see the randomisation list in advance. 
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3.3 Data collection, management and analysis 
3.3.1 Data collection methods 
3.3.1.1 Recruitment rate 
We will record the number of practices approached, recruited and analysed. 
 
3.3.1.2 Data relating to intervention delivery from questionnaires 
Electronic questionnaires will be sent to all intervention practices in CPRD, ResearchOne 
and London-based practices.   
 
3.3.1.3 Data relating to measurement of exposure and outcome 
CPRD: In practices that contribute data to the CPRD, all exposure and outcome data will be 
ascertained through the anonymised electronic healthcare records, which are routinely 
uploaded by the practice into the database.  We will collect data on age, sex, clinical risk 
group, vaccination reminder type (text, letter, phone call, face to face), vaccination uptake, 
death, transfer out of practice, flu and flu-like illness, and hospital admissions.  Follow-up for 
practices will be complete using this method. 
ResearchOne: In practices that contribute data to ResearchOne, all exposure and outcome 
data will be ascertained through the anonymised electronic healthcare records, which are 
routinely uploaded by the practice into the database.  We will collect data on age, sex, 
clinical risk group, vaccination reminder (text, letter, phone call, face to face),vaccination 
uptake, death, transfer out of practice, flu and flu-like illness, and hospital admissions.  
Follow-up for all practices will be complete using this method. 
For practices that do not join or withdraw from ResearchOne, we will approach the data 
provider (TPP SystmOne) directly to request a one-off data extract, or ask a practice 
administrator to extract the data for us.  All data will be anonymised,  
Practices in London using iPlato software: Within London practices, ascertainment of 
exposure and outcome data will be tested through a number of methods because it is an 
objective of this trial to establish the best approaches for data collection based on ease of 
collection, cost and time.  Approaches that we will use are: 
(i) The GP extraction service;8 
(ii) iPlato data collection; 
(iii) Practice data interrogation by a member of research staff or practice 
administrator. 
(iv) The EMIS data extraction service; 
(v) The Vision data extraction service; 
(vi) MIQUEST data extraction tool. 
Data required are age, sex, clinical risk group, vaccination reminder (text, letter, phone call, 
face to face), vaccination uptake, death, transfer out of practice, flu and flu-like illness, and 
hospital admissions.  
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3.3.2 Data management 
Data from the online questionnaires will be imported into a spreadsheet for analysis.  These 
and all other practice electronic data will be stored inside a secure network at the London 
School of Hygiene and Tropical Medicine. 
Trial consent forms, questionnaires and any correspondence with practices will be stored in 
locked filing cabinets at the Trial Coordinating Centre at the London School of Hygiene and 
Tropical Medicine.  Only trial staff will have access to these. 
3.3.3 Statistical methods 
3.3.3.1 Primary outcome 
We will compare vaccine uptake in the intervention and control groups using a t test. 
A cluster-level analysis will be performed using practice specific proportions as observations.  
We will compare vaccine uptake in the intervention and standard care groups using a t test, 
with the size of clusters taken into account.    
Although the study will be carried out in three settings, the analysis will not be stratified by 
setting.  This is because the settings are identical in terms of the intervention used, the 
vaccine used and the vaccine targets. The only differences between the settings are the GP 
software system used by the practice.  Since this will not influence vaccine uptake, there is 
no justification to stratify by setting.  
3.3.3.2 Secondary outcomes 
Across each of the three study settings, a series of descriptive statistics will be produced.  
Descriptive statistics will include: 
 Recruitment rate:  
 Number and proportion of patients within each risk group that were sent the text 
message; 
 Proportion of practices experiencing difficulties sending the text message; 
 Proportion of practices experiencing patient complaints; 
 Proportion of practices describing the intervention as worthwhile; 
 Proportion of practices open to participation in another text messaging trial; 
 Average cost of delivering intervention; 
 Cost and time required for ascertaining practice data;   
 Proportion of patients who complained (sub-study data), 
3.3.3.3 Sensitivity and subgroup analyses 
Our primary analysis will be an intention to treat analysis.  However, to account for any 
contamination between the standard care and intervention arms, we will carry out a per-
protocol analysis. 
Where available, we will also measure the difference in vaccine uptake, comparing practices 
that used the exact wording of the message in the study protocol with practices that used an 
alternative message.  We hypothesise that practices using our message (based on 
behavioural theory) will have a higher uptake than an alternative designed by the practice.   
As this will be a non-randomised comparison, we will adjust for confounders. 
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Finally, we will compare the effectiveness of the text message based on the time of day that 
it was sent to patients.  We hypothesise that messages sent in the late afternoon will have 
more effect that those sent at earlier times of day, when patients may not have the time to 
respond. 
3.3.3.4 Hawthorne effect 
The study design allows an evaluation of the generalisibility of the study population; 
practices that take part in the study can be compared to other practices outside of the trial 
that contribute data to ResearchOne and CPRD. We will test whether participation in the trial 
changes the behaviour of practices in their use of text messaging (Hawthorne effect). 
This study will provide evidence regarding the effectiveness of text messaging reminders for 
influenza vaccine in patients under 65 with chronic conditions.  The methodology here will be 
applied to future cluster randomised trials of text messaging interventions within electronic 
heath records. 
 
3.3.4 Monitoring 
The Trial Management Group will oversee the work of the coordinating centre and will meet 
regularly in person or by teleconference, to monitor the progress of the trial and to deal with 
any practical issues. 
No Trial Steering Committee will be convened.   
 
3.3.5 Data monitoring 
An independent data monitoring and ethics committee (DMC) is not required for this trial.   
 
3.3.6 Patient or usergroup involvement 
We will consult with two lay members of the Steering Commitee of two CPRD trials that are 
currently underway. 
 
4 Ethics and dissemination 
4.1 Research ethics approval 
The trial has research ethics committee approval for the UK and is gaining R&D approval 
from all sites. Potentially eligible practices will be provided with information about the trial to 
consider for up to one month. Informed consent will be sought prior to randomisation.   
Approval has also been sought from the LSHTM ethics committee and the ResearchOne 
Projects Committee. 
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4.2 Protocol amendments 
Any amendments will be submitted for approval to the appropriate bodies  
 
4.3 Consent  
Self-completion consent forms (attached in Appendix 5.1) will be mailed to practices, 
returnable to the Chief Investigator at the London School of Hygiene and Tropical Medicine.    
 
4.4 Confidentiality 
Patient and practice data will be stored as described in section 3.3.2.  Any identifiable patient 
data will be anonymised and stored inside a secure network.  Access to data will be 
controlled. 
 
4.5 Declaration of interests 
No competing interests declared. 
 
4.6 Access to data 
The data will be accessed by authorised persons from the London School of Hygiene & 
Tropical Medicine of research governance authorities to check that the study is being carried 
out correctly. All will have a duty of confidentiality and no data will be disclosed outside the 
research site.  All patient- and practice-level information will be kept strictly confidential.  
 
4.7 Dissemination policy 
The results of the trial will be published in peer reviewed journals and a report will be 
disseminated to all participating practices. 
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5 Appendices 
5.1 Informed consent materials 
Informed Consent Form for Practices 
Practice name: _____________________________________________________________________ 
Practice address:____________________________________________________________________ 
__________________________________________________________________________________ 
__________________________________________________________________________________ 
 
Please could you provide the email address of practice member of staff who will take responsibility for 
the text message campaign?___________________________________________________________ 
 
 
Study Protocol Number: 2.4 
Clinicaltrials.gov number: 
Full Title of Project: A cluster randomised trial of text messaging reminders for influenza vaccine in 
patients under 65 in clinical risk groups in English primary care. 
Name of Principal Investigator: Liam Smeeth 
 
Please initial box 
1. I confirm that I have read and understand the practice information sheet dated 
22/08/2013 (version 2.5) for the above study. I have had the opportunity to 
consider the information, ask questions and have had these answered fully. 
 
 
2. I understand that my practice’s participation is voluntary and we are free to 
withdraw at any time, without giving any reason, without our legal rights being 
affected. 
 
 
3. I understand that vaccine uptake data collected during the study may be looked at 
by responsible individuals from the London School of Hygiene and Tropical 
Medicine, from regulatory authorities or from the NHS Trust, where it is relevant to 
taking part in this research. I give permission for these individuals to access our 
practice records.   
 
 
4. I agree to our practice taking part in the above study.  
 
 
 
 
 
__________________________   ____________________  ________________ 
Name of Person giving consent   Signature    Date 
 
1 copy for practice (original); 1 copy for Principal Investigator  
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7 Read code lists 
The following are Read code lists that we will use to ascertain text message exposure and 
vaccine uptake outcome data in the Clinical Practice Research Datalink and ResearchOne 
datasets. 
 
7.1 Influenza vaccination 
 
Read code Read term 
65E..00 influenza vaccination 
65E2.00 influenza vaccination given by other healthcare provider 
65E2000 Seasonal influenza vaccination given by other healthcare provider 
65ED.00 Seasonal influenza vaccination 
65ED000 Seasonal influenza vaccination 
9OX8.00 has influenza vaccination at work 
ZV04800 [v]influenza vaccination 
ZV04811 [v]flu - influenza vaccination 
In addition to these Read codes, influenza vaccination will be based on therapy codes using 
BNF codes 14.4.2 (Vaaccines and Antisera – influenza vaccines) 
 
 
7.2 Text message vaccination reminder 
 
Read code Read term 
9OXC.00 influenza vaccination invitation sms text message sent 
9OXC100 influenza vaccination invitation 1st sms text message sent 
9OXC200 influenza vaccination invitation 2nd sms text message sent 
9OXC300 influenza vaccination invitation 3rd sms text message sent 
 
 
